Low-intensity extracorporeal shockwave therapy — usually just called "shockwave therapy," and sold under brand names like GAINSWave at men's health clinics — is marketed as a drug-free, one-time fix for erectile dysfunction that treats the "root cause" instead of masking symptoms the way PDE5 inhibitors do. The honest picture from the clinical literature is messier than that pitch. A 2026 Cochrane review — the most rigorous evidence standard in medicine — rates the proof behind it as low-certainty, and two meta-analyses published the same year, looking at overlapping sets of trials, reach different conclusions about whether the effect is big enough to matter [1][2].
What's Your Prostate Risk Score?
Take ManCore's free 6-question risk assessment. Get your personal risk score, see which supplements are most relevant to your profile, and get a clear action plan — in under 2 minutes.
What Shockwave Therapy Is Supposed to Do
Low-intensity shockwave therapy (LI-ESWT, sometimes LiSWT or LiST) delivers low-energy acoustic pulse waves to the penile tissue through a handheld probe — a much weaker energy level than the shockwaves used to break up kidney stones. The proposed mechanism is that the pulses trigger microtrauma that stimulates angiogenesis (new blood vessel growth) and the release of growth factors, theoretically improving blood flow to erectile tissue over time rather than just enabling an erection in the moment. Protocols vary by clinic, but typically run 6-12 sessions over several weeks, aimed specifically at vasculogenic ED (erectile dysfunction caused by restricted blood flow) rather than the psychogenic or neurogenic forms.
What the Highest-Quality Evidence Actually Shows
The strongest available summary is a 2026 Cochrane review — Cochrane reviews are widely considered the gold standard for evaluating medical evidence because of their strict inclusion criteria and formal certainty grading. Pooling 21 randomized controlled trials covering 1,357 men, it found that LI-ESWT "may slightly improve" short-term erectile function (IIEF-EF score, mean difference of 3.89 points) and that long-term function "may improve" more (mean difference of 5.25 points) — but graded both findings as low-certainty evidence, explicitly noting that "clinical importance is uncertain" for the short-term result [1]. On the reassuring side, the same review found little difference in treatment discontinuation or adverse events compared to sham treatment — whatever else is true, LI-ESWT appears to carry low physical risk [1].
- •"Low-certainty" in GRADE terminology (the framework Cochrane uses) means further research could change the estimate meaningfully — it doesn't mean the therapy has been shown not to work, but it does mean clinics presenting it as settled science are overstating the evidence
- •The gap between statistical significance and clinical significance matters here: an average improvement can be real and still be too small for an individual patient to notice or care about
- •Evidence certainty was downgraded mainly for methodological limitations and heterogeneity across trials — different devices, energy levels, and protocols — not because trials consistently failed to show any effect
Where the Meta-Analyses Disagree
This is the part clinic marketing pages leave out: researchers looking at similar pools of trials don't agree on what the data means. A 2026 systematic review and meta-analysis in the World Journal of Men's Health, covering 12 RCTs, found statistically significant improvement in IIEF scores — but concluded that "clinical relevance is limited for most patients" and that "current evidence does not support its routine inclusion in ED treatment algorithms." Notably, this analysis found no significant improvement in penile Doppler ultrasound measurements (blood flow velocity and resistive index) — which undercuts the specific "restores blood flow" mechanism the therapy is sold on, since the functional score improved without a matching vascular change showing up on imaging [2]. A 2025 meta-analysis in Future Science OA, pooling a similar-sized set of 12 RCTs and 882 men, reached a more favorable reading of comparable data, concluding the results "support the role of LI-ESWT as a potential treatment" [3]. Same general evidence base, different verdicts about whether the improvement is one a patient would actually feel.
The clinic marketing you'll see rarely mentions that meta-analyses published in the same year disagree about whether the benefit is clinically meaningful, or that one of them found no measurable change in penile blood flow itself. Before paying out of pocket for a multi-session package, get a real baseline of your own erectile function with a validated score rather than relying on how you feel in the moment — that's exactly what the ManCore dashboard is built for.
Combining It With a PDE5 Inhibitor
For men already on a PDE5 inhibitor who are weighing whether to add shockwave therapy, a 2024 double-blind, sham-controlled trial gives a more grounded answer than the general meta-analyses. Forty-eight men with severe vasculogenic ED, all taking daily tadalafil 5mg, were randomized to add either real LI-ESWT or sham therapy. At 3 months, the real-treatment group scored higher on the IIEF-EF (12.9 vs 10.8, a statistically significant difference) — but that roughly 2-point gap is well below the 7-point threshold researchers generally consider a minimal clinically important difference on that scale. No adverse events occurred in either group [4]. Read plainly: adding shockwave therapy produced a measurable but modest extra benefit on top of a PDE5 inhibitor in men with severe ED — not a transformative one.
The Practical Reality Before You Book a Package
- •The evidence base is strongest for mild-to-moderate vasculogenic ED — it is not well-supported for severe, purely psychogenic, or neurogenic ED (e.g., after prostatectomy nerve damage)
- •Protocols differ enormously between clinics — device model, energy level, number of sessions, and treatment sites are not standardized — which is a major reason the meta-analyses pooling these trials disagree with each other
- •In the US, the devices used are FDA-cleared for other indications (such as musculoskeletal pain); their use for ED is generally off-label, which matters when a clinic's marketing implies formal approval for this purpose
- •Cost is almost always out-of-pocket and not covered by insurance — published protocols commonly run 6-12 sessions, and clinics frequently sell multi-thousand-dollar packages upfront
- •A 2023 narrative review of the literature summarized the state of the evidence bluntly: "little scientific evidence but suggests good results," recommending clinicians and patients "remain cautious until a larger volume of higher quality studies" clarifies which patients actually benefit [5]
Related Reading
What Is Erectile Dysfunction? Causes, Symptoms & Complete Overview
Background on vasculogenic vs. psychogenic and neurogenic ED, relevant to who shockwave therapy is and isn't likely to help.
Erectile Dysfunction Treatment: Every Option Explained (2026)
How shockwave therapy fits alongside PDE5 inhibitors, pumps, injections, and other established ED treatments.
How Long Does Erectile Dysfunction Treatment Take to Work? A Realistic Timeline
Realistic timelines for other ED treatments, useful context against shockwave therapy's multi-week session protocols.
Supplements for Circulatory Support
Snap Supplements Nitric Oxide Booster + Prostate Health
Supports healthy circulation and nitric oxide production — a lower-cost, evidence-modest complement to discuss with your doctor while you weigh pricier procedural options.
Male Optimization Formula
General men's health formula worth discussing with your doctor as part of a broader plan; not a substitute for evaluating the underlying cause of ED.
Affiliate disclosure: ManCore earns a small commission on purchases made through these links at no extra cost to you.
Frequently Asked Questions
Does shockwave therapy actually work for ED?
The evidence is genuinely mixed. A 2026 Cochrane review found low-certainty evidence of a slight short-term and larger long-term improvement in erectile function scores, but explicitly called the clinical importance of the short-term result uncertain. A separate 2026 meta-analysis concluded the benefit is too limited to support routine use, while a 2025 meta-analysis of a similar trial pool was more favorable. It may help some men with mild-to-moderate vasculogenic ED, but it is not the settled, guaranteed fix clinic marketing often implies [1][2][3].
Is shockwave therapy for ED FDA-approved?
The devices themselves are typically FDA-cleared for other uses, such as musculoskeletal pain treatment. Their use for erectile dysfunction in the US is generally considered off-label, which is worth knowing when a clinic's marketing implies the treatment itself has formal approval for ED specifically.
How much does shockwave therapy for ED cost, and is it covered by insurance?
It's almost always paid out of pocket. Clinics commonly sell packages covering 6-12 sessions delivered over several weeks, often priced in the low thousands of dollars total. Insurance coverage is uncommon because it isn't an FDA-approved indication for this use.
Is shockwave therapy safe?
The safety data is genuinely reassuring — the 2026 Cochrane review found little difference in treatment discontinuation or adverse events compared to sham treatment. The open question is effectiveness and value for money, not physical safety [1].
Should I try shockwave therapy before or instead of a PDE5 inhibitor like sildenafil or tadalafil?
There's no evidence it should replace a PDE5 inhibitor as a first-line option. A 2024 sham-controlled trial found it produced a modest additional benefit on top of daily tadalafil in men with severe ED — useful information for someone already on a PDE5 inhibitor and considering whether to add it, but not a reason to skip established first-line treatment to try shockwave therapy alone [4].
Who is shockwave therapy least likely to help?
The evidence base is weakest for severe ED, purely psychogenic ED, and neurogenic ED (such as after prostatectomy nerve damage) — the therapy's proposed mechanism targets blood-flow-related (vasculogenic) causes specifically. Men in these categories are the ones most likely to be paying for a procedure the evidence doesn't actually support for their situation.
The Bottom Line
Shockwave therapy for ED sits in a genuinely unsettled place in the evidence, not the clear-cut win clinic marketing suggests. The most rigorous available review rates the proof as low-certainty, and researchers looking at overlapping trial data disagree about whether the effect is large enough to matter to an actual patient. The safety profile is reassuring, and men with mild-to-moderate vasculogenic ED have the best-supported case for trying it — but go in knowing you're paying out of pocket for a treatment the field itself hasn't reached consensus on, and get a real baseline measurement before you start so you can judge your own results rather than taking a clinic's word for it.